-Vaccination of individuals with naturally acquired immunity at the expense of others without any immune protection is inherently inequitable. This is the basis for the argument to delay vaccination against SARS-CoV-2 in individuals who have had confirmed symptomatic COVID-19, made in the peer-reviewed journal Viral Immunology. Click here to read the article now
Martin Krask, MD, University of Colorado Anschutz Medical Campus, and coauthors state that, "Low vaccine production capacity complicated by inefficiencies in vaccine administration suggests that vaccinating preferentially those without any prior protection will result in fewer natural infections more rapidly." The proportion of individuals with confirmed symptomatic COVID-19 who experience re-infection appears to be low. "The speed of vaccination is all the more important now after we have learned that the more time the virus has-the more escape mutations are likely to challenge effective immunity," conclude the authors.
"The question of whether or not to vaccinate those who have had natural infection with SARS-CoV-2 is a timely one. An individual who cleared the virus will likely have made a broad immune response against it, so we might find that a single dose is sufficient for such individuals," says Rodney S. Russell, PhD, Editor-in-Chief of Viral Immunology, from Memorial University of Newfoundland, St. John's.
About the Journal
Viral Immunology is an authoritative peer-reviewed journal published ten times a year in print and online. Topics cover both human and animal viral immunology, exploring viral-based immunological diseases, pathogenic mechanisms, and virus-associated tumor and cancer immunology. The Journal includes original research papers, review articles, and commentaries covering the spectrum of laboratory and clinical research and exploring developments in vaccines and diagnostics targeting viral infections. Tables of content and a sample issue may be viewed on the Viral Immunology website.
About the Publisher
Mary Ann Liebert, Inc., publishers known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research. Its biotechnology trade magazine, GEN (Genetic Engineering & Biotechnology News), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's more than 100 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.
